To conclude, AR signaling plays a key role in HCC progression and the sexual dimorphism of the disease; however, therapeutically targeting the AR-axis has thus far been unable to effectively treat HCC due to the combined effects of induced AR expression, post-translational ligand-independent AR-activation, and the presence of ligand-independent constitutively active AR-SVs. This evidence concerns the gene AR and hepatocellular carcinoma.